ResearcherAichi Cancer CenterActive in the last 2 years
Nobuhiro Hieda
Matched on OpenAlex author ID A5110296401. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Co-author DOI 10.1038/s41416-024-02794-5↗
- Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.04.007↗
- Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.05.007↗
- [The clinical practice for the diagnosis of pancreatic cancer]. Co-author PMID 25856997↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nobumasa Mizuno · 3 shared papers, 2015–2016 · strength 0.19
- Paper [The clinical practice for the diagnosis of pancreatic cancer]. PMID 25856997↗
- Paper Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- Paper Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective coho… DOI 10.1016/j.pan.2016.05.007↗
- Kenji Yamao · 3 shared papers, 2015–2016 · strength 0.19
- Paper [The clinical practice for the diagnosis of pancreatic cancer]. PMID 25856997↗
- Paper Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- Paper Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective coho… DOI 10.1016/j.pan.2016.05.007↗
- Toshinao Itani · 1 shared paper, 2024 · strength 0.13
- Kozo Ikuta · 1 shared paper, 2024 · strength 0.13
- Kosuke Minaga · 1 shared paper, 2024 · strength 0.13
- Munenori Kawai · 1 shared paper, 2024 · strength 0.13
- Toshihiro Morita · 1 shared paper, 2024 · strength 0.13
- Yukitaka Yamashita · 1 shared paper, 2024 · strength 0.13
- Takahisa Maruno · 1 shared paper, 2024 · strength 0.13
- Atsushi Umemura · 1 shared paper, 2024 · strength 0.13
- Hiroshi Seno · 1 shared paper, 2024 · strength 0.13
- Makoto Sono · 1 shared paper, 2024 · strength 0.13
- Shujiro Yazumi · 1 shared paper, 2024 · strength 0.13
- Masaya Ohana · 1 shared paper, 2024 · strength 0.13
- Akihisa Fukuda · 1 shared paper, 2024 · strength 0.13
- Masatoshi Kudo · 1 shared paper, 2024 · strength 0.13
- Susumu Hijioka · 2 shared papers, 2016 · strength 0.10
- Paper Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- Paper Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective coho… DOI 10.1016/j.pan.2016.05.007↗
- Kazuo Hara · 2 shared papers, 2016 · strength 0.10
- Paper Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- Paper Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective coho… DOI 10.1016/j.pan.2016.05.007↗
- Hiroshi Imaoka · 2 shared papers, 2016 · strength 0.10
- Paper Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- Paper Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective coho… DOI 10.1016/j.pan.2016.05.007↗
- Seiji Natsume · 1 shared paper, 2016 · strength 0.05
- Nozomi Okuno · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.